W F Baptist Health
Welcome,         Profile    Billing    Logout  
 8 Trials 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Urbanic, James
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
ProsRSI, NCT04349501: Biomarker Monitoring of Prostate Cancer Patients With RSI MRI

Recruiting
2
100
US
Restriction Spectrum Imaging Magnetic Resonance Imaging, RSI-MRI
University of California, San Diego
Prostate Cancer
12/24
12/26
CHIO3, NCT04062708: Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Active, not recruiting
2
38
US
Durvalumab, Imfinzi, Surgery, Radiotherapy
Alliance Foundation Trials, LLC., AstraZeneca
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
12/25
06/26
NCT01766297: Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Recruiting
2
132
US
Proton Radiotherapy
Proton Collaborative Group
Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
01/25
01/33
AFT-57, NCT05798663: Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Recruiting
2
178
US
Atezolizumab, Tecentriq, L01XC32, Tiragolumab
Alliance Foundation Trials, LLC., Genentech, Inc.
NSCLC
08/25
10/27
RADCOMP, NCT02603341: Pragmatic Randomized Trial of Proton Vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer: a Radiotherapy Comparative Effectiveness () Consortium Trial

Active, not recruiting
N/A
1238
US
Photon, Proton
Abramson Cancer Center at Penn Medicine, Patient-Centered Outcomes Research Institute
Breast Cancer
08/28
11/36
PCG 001-09, NCT01255748: Registry Study for Radiation Therapy Outcomes

Recruiting
N/A
40000
US
Proton Therapy, Photon Therapy, SRS, Brachytherapy
Proton Collaborative Group
Neoplasms
06/39
 
Weaver, Kathryn
NCT05877404: Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer

Terminated
N/A
112
US
Surveys
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Endometrial Cancer
02/24
02/24
NCT05796518: Feasibility of a Patient Directed Tool to Assess Heart Health Among Endometrial Cancer Survivors

Completed
N/A
42
US
PREVENT Cardiovascular Health Assessment Tool, Survey, Interview Regarding Heart Health
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Endometrial Cancer, Survivorship
06/24
06/24
AH-HA, NCT03935282: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

Active, not recruiting
N/A
645
US
AH-HA Tool in the EPIC EHR
Wake Forest University Health Sciences, National Cancer Institute (NCI), Washington University School of Medicine, University of Texas Southwestern Medical Center
Breast Neoplasm, Prostatic Neoplasm, Colorectal Neoplasms, Endometrial Neoplasms, Hodgkin Disease, Non Hodgkin Lymphoma
03/25
03/25
HRSN, NCT06412029: Understanding and Enhancing Health-Related Social Needs () Screening Among Community Oncology Practices

Enrolling by invitation
N/A
144
US
Non-Interventional
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Cancer
08/26
11/26
CONNECT, NCT06383988: A Web-based Program to Help Caregivers of Lung Patients Learn About Available Supportive Care Resources

Enrolling by invitation
N/A
240
US
Support for Caregiver - Generic List, Support for Caregiver - Personalized List, Internet-Based Intervention - CONNECT, Patient Navigation, Patient Navigator Program
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Stage II Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
10/25
01/26
NCT04395495: RASopathy Biorepository

Recruiting
N/A
1000
US
Children's Hospital Medical Center, Cincinnati
RAS Mutation, Neurofibromatosis 1, Noonan Syndrome, Noonan Syndrome With Multiple Lentigines, Noonan Neurofibromatosis Syndrome, Cardiofaciocutaneous Syndrome, Costello Syndrome, Legius Syndrome, Smith-Kingsmore Syndrome, MTOR Gene Mutation, GATOR-1 Gene Mutation, SYNGAP1-Related Intellectual Disability, DLG4, MAPK1 Gene Mutation
12/65
12/65

Download Options